S. Krishnaswami

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Toni K. Choueiri, Robert J. Motzer, Brian I. Rini et al. · Annals of Oncology · 2020 · 461 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

Kim Papp, Alan Menter, Bruce Strober et al. · British Journal of Dermatology · 2012 · 336 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

D L Boyle, K. Soma, J Hodge et al. · Annals of the Rheumatic Diseases · 2014 · 298 citations · Full text

Medicine, Pathobiology, Pharmacology +17

Firm growth and its determinants

Priya Gupta, Samapti Guha, S. Krishnaswami · Journal of Innovation and Entrepreneurship · 2013 · 274 citations · Full text

Business, Business Economics, Business Strategy +9

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Peter A. Milligan, Marcy Brown, B Marchant et al. · Clinical Pharmacology & Therapeutics · 2013 · 236 citations

Medicine, Pharmacology, Clinical Pharmacology +10